MELDUNG VOM 04.12.2017 16:20
Meldung drucken Artikel weiterleiten
pta20171204029
Business news for the stock market
Pressefach Pressefach

Biofrontera AG: Biofrontera to Present at the 10th Annual LD Micro Main Event

Leverkusen (pta029/04.12.2017/16:20) - Biofrontera AG (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced that the Company is scheduled to present at the 10th Annual LD Micro Main Event, being held on December 5-7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Thomas Schaffer, the Company's Chief Financial Officer, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Details for the presentation are as follows:

Date: Thursday, December 7, 2017
Time: 9:00AM PST
Location: Track 3

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
press@biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker
+49 (0) 152 08931514

IR UK: Seton Services
Toni Vallen
+44(0) 20 7729 0805

IR and PR US: The Ruth Group
IR: Tram Bui
+1 646-536-7035
PR: Kirsten Thomas
+1 508-280-6592

About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 130 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).

http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(Ende)

Aussender: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Deutschland
Ansprechpartner: Investor & public relations
Tel.: +49 (0) 214 87 63 20
E-Mail:
Website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
Börsen: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Biofrontera AG
AKTUELLE BUSINESS NEWS
15.12.2017 13:52
Kryptowährung Bitcoin jetzt 18.000 Dollar wert
pressetext.redaktion
15.12.2017 06:15
Avatar als Lustobjekt aus VR-Headsets gelöscht
pressetext.redaktion
14.12.2017 15:00
Bilanz 2016: "Unsere Strategie ist aufgegangen"
DSER - Deutsche Software Engineering & Research GmbH
14.12.2017 12:30
Innovationszentren allein machen nicht erfinderisch
pressetext.redaktion
14.12.2017 11:00
Arvato Financial Solutions schließt Partnerschaft mit Shopware
Arvato infoscore GmbH - part of Arvato Financial Solutions
Weitere News anzeigen